ライフサイエンスコーパス: exendin-4

1 rents were no longer potentiated by GLP-1 or exendin-4.

2 ed in TTX, it was still enhanced by GLP-1 or exendin-4.

3 by 0.01-1 nmol/L GLP-1 and by 0.5-100 nmol/L exendin-4.

4 gn-3 blocked the proliferation stimulated by exendin-4.

5 administration of a GLP-1 receptor agonist, exendin-4.

6 mally to peripherally administered GLP-1 and exendin-4.

7 e signaling-1 (SOCS1)] were also elevated by exendin-4.

8 yntomodulin, and the clinically used mimetic exendin-4.

9 intravenous administration with ABP/TSTA-SP-exendin-4.

10 uated in vitro after delivery of ABP/TSTA-SP-exendin-4.

11 cit in ischemic rats treated with vehicle or exendin-4.

12 ted in 82% of the beta-cells pretreated with exendin-4.

13 in 86% of NOD mice treated with both CFA and exendin-4.

14 pancreatectomy, low-dose streptozotocin, or exendin-4.

15 e motif, a 20-residue C-terminal sequence of exendin-4.

16 ificantly reduced in ob/ob-treated mice with Exendin-4.

17 roup in the mutant receptor with the peptide exendin-4.

18 MIN6B1 cells in response to the GLP-1 analog exendin-4.

19 also essential for the protective effects of exendin-4.

20 in multiple system atrophy mice treated with exendin-4.

21 tion of fluorescence-labelled GLP-1 analogue exendin-4.

22 administration of the GLP-1 receptor agonist exendin-4 (0.05 mug) significantly reduced cocaine, but

23 red the effect of repeated administration of exendin-4 (0.5 mug/kg, intraperitoneal twice a day for 7

24 or their lean littermates, were treated with Exendin-4 [10 microg/kg or 20 microg/kg] for 60 days.

25 tion of (111)In-[Lys40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinom

26 Unlike the radiometal-labeled exendin-4, (18)F-TTCO-Cys(40)-exendin-4 has much lower k

27 pre-administration of the GLP-1R antagonist Exendin-4(3-39).

28 ng with [Nle(14),Lys(40)(Ahx-DOTA-(68)Ga)NH2]exendin-4 ((68)Ga-DOTA-exendin-4) is feasible and sensit

29 atiation signals, including cholecystokinin, exendin-4 (a glucagon-like peptide-1 receptor agonist),

30 r smad 2 and/or smad 3, as well as exogenous exendin-4 (a long-acting glucagon-like peptide-1 agonist

31 Exendin-4, a 39 amino acid peptide originally isolated f

32 Serotonin depletion impaired the ability of exendin-4, a clinically used GLP-1 analog, to reduce bod

33 ides made up of glucagon and either GLP-1 or exendin-4, a GLP-1 agonist, was engineered.

34 We studied effects of GLP-1 and exendin-4, a GLP-1 receptor agonist, on gamma-aminobutyr

35 nd a similar hypophagic response to systemic Exendin-4, a GLP1R agonist that crosses the blood-brain

36 n of the beta-cell toxin streptozotocin, and exendin-4, a glucagon-like peptide 1 (GLP-1) agonist.

37 (mGluR) agents in relation to the effects of exendin-4, a glucagon-like peptide 1 analogue, cholecyst

38 [(68)Ga]DO3A-VS-Cys(40)-Exendin-4, a glucagon-like peptide 1 receptor agonist, w

39 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor ag

40 Here we investigated whether the addition of exendin-4, a hormone that stimulates insulin secretion a

41 diabetic NOD mice were treated with CFA and exendin-4, a potent analog of glucagon-like peptide-1.

42 In the micelle-bound state of exendin-4, a single helix (residues 11-27) is observed w

43 te that the glucagon-like peptide-1 analogue exendin-4, a well-tolerated and Federal Drug Agency-appr

44 nt of overtly diabetic NOD mice with ALS and exendin-4 achieved complete remission in 23 of 26 mice (

45 exia and body weight loss induced by central exendin-4 administration in a rat.

46 Increased HPFv GLP-1R activity following exendin-4 administration potently reduced food intake (b

47 in Glp1r(-/-) recipient mice, whereas acute exendin-4 administration robustly induced the expression

48 No treatment or exendin-4 alone failed to produce remission.

49 o short-term treatment with the GLP-1 analog exendin-4 also declined with age.

50 Exendin-4 also protected against protein kinase Cdelta-m

51 Exendin-4, also, has a longer half-life than GLP-1, due

52 was triggered by the GLP-1 receptor agonist exendin-4, an effect mimicked by caffeine, Sp-cAMPS or f

53 pared with the stable GLP-1 and CCK mimetics exendin-4 and (pGlu-Gln)-CCK-8, respectively.

54 )NH2]exendin-4, and [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 perfo

55 te the use of a newly created fusion gene of exendin-4 and alpha1-antitrypsin to control obesity and

56 The GLP-1 effects were mimicked by exendin-4 and antagonized by exendin-9-39.

57 2 (Skp2) were assessed in mice treated with exendin-4 and in a mouse model with specific upregulatio

58 erance effects of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse li

59 Met-303 was more important for exendin-4 and oxyntomodulin action than those of GLP-1 p

60 nding and signaling of the peptide mimetics, exendin-4 and oxyntomodulin, as well as small molecule a

61 racer is based on the amino acid sequence of exendin-4 and targets the glucagon-like peptide-1 recept

62 Peptides, including glucagon-like peptide-1/exendin-4 and the combination of epidermal growth factor

63 The coapplication of exogenous exendin-4 and, specifically, low-dose exogenous TGF-beta

64 eference compound [Lys40-(AHX-DTPA-111In)NH2]exendin-4 and, thus, represent potential new tracers for

65 ceptor affinity for [Lys40-(AHX-DFO-68Ga)NH2]exendin-4, and [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 and [L

66 gic, less sensitive to hypophagic effects of exendin-4, and expended more energy with diminished sens

67 N171-82Q HD mice were treated with insulin, Exendin-4, and the newly developed GLP-1-Tf to determine

68 In conclusion, Exendin-4 appears to effectively reverse hepatic steatos

69 on doses from the novel tracer (68)Ga-NODAGA-exendin-4 are very low for adults and children.

70 urther validation of [(68)Ga]DO3A-VS-Cys(40)-Exendin-4 as an islet imaging probe for future clinical

71 ynomolgus pancreas after coinjection of DO3A-exendin-4 at 0.15-20 mug/kg ranged from 49% to 97%, as e

72 arable to that of [Lys40-(AHX-DTPA-111In)NH2]exendin-4 at 1-48 h after injection.

73 90% (P < 0.0001) by coadministration of DO3A-exendin-4 at 100 mug/kg.

74 n of the kidneys, a known characteristic for exendin-4-based radiotracers.

75 trast, no tertiary structure is evident when exendin-4 binds to DPC micelles.

76 G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced beta-ar

77 mitotic effector) observed after exposure to exendin-4, but not that of PDX-1 or VEGF-A/C.

78 was predicted to be important for GLP-1- and exendin-4-, but not oxyntomodulin-mediated cAMP formatio

79 ne reduced the renal accumulation of (111)In-exendin-4 by 18.1%, whereas the pancreatic uptake remain

80 In rodents, and possibly in humans, exendin-4 can stimulate beta-cell proliferation.

81 ignificant uptake of [(68)Ga]DO3A-VS-Cys(40)-Exendin-4 compared to the livers of untreated mice; and

82 ormation of these nanoparticles relies on TA/exendin-4 complexation and stabilization through TA-Fe(3

83 Toward this goal, we synthesized an exendin-4 conjugated magnetic iron oxide-based nanoparti

84 Although exendin-4 could also stimulate actin remodeling, this wa

85 In Tg mice, exendin-4 decreased levels of hippocampal IRS-1pSer and

86 (18)F-TTCO-Cys(40)-exendin-4 demonstrated its great potential for transplan

87 (18)F-TTCO-Cys(40)-exendin-4 demonstrated specific binding to GLP-1R.

88 An exendin-4 derivative conjugated to desferrioxamine (DFO)

89 emonstrated the potential of radiometallated exendin-4 derivatives for the imaging of glucagonlike pe

90 The aim of this work was the development of exendin-4 derivatives for the imaging of insulinomas by

91 Recently investigated exendin-4 derivatives were radiolabeled with the SPECT i

92 Finally, exendin-4 did not alter the analgesic effects of oxycodo

93 ze, and likely do not involve nausea as HPFv exendin-4 did not induce a conditioned flavor avoidance.

94 tent with our systemic studies, infusions of exendin-4 directly into the accumbens shell attenuated o

95 activity led to a more potent attenuation of exendin-4 effects on food intake.

96 Exendin-4 enhanced the effect of CFA on reversing diabet

97 eptide-1 (GLP-1) and the long-acting agonist exendin 4 (Ex-4) expand beta-cell mass by stimulating ne

98 a 2-week administration of the GLP-1 analog exendin 4 (ex-4) induced an almost complete ablation of

99 agon-like-peptide-1 (GLP-1) receptor agonist exendin-4 (Ex-4) and was accompanied by quantal secretor

100 Treatment with exendin-4 (Ex-4) delivered by subcutaneous micro-osmotic

101 ed that administration of the GLP-1R agonist exendin-4 (Ex-4) directly into the LDTg significantly at

102 c voltammetry showed that the GLP-1R agonist exendin-4 (Ex-4) does not alter dopamine release in the

103 Exendin-4 (Ex-4), a GLP-1 receptor agonist, was then fus

104 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) rece

105 We found that exendin-4 (Ex-4), an agonist of the glucagon-like peptid

106 he GLP-1 receptor agonist and cAMP stimulus, exendin-4 (Ex-4), could rescue beta-cell replication and

107 on of a pancreatic beta-cell trophic factor, exendin-4 (Ex-4), during the prediabetic neonatal period

108 long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of anti

109 toneal administration of the GLP-1R agonist, exendin-4 (Ex-4), on food intake in OP and obese-resista

110 ic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be ac

111 roitin sulfate-g-glycocholic acid-coated and Exendin-4 (Ex-4)-loaded liposomes (EL-CSG) were prepared

112 or the more stable exogenous GLP-1R agonist exendin-4 (Ex-4).

113 the glucagon-like peptide-1 receptor agonist Exendin 4 (Ex4) protects hepatocytes from ischemia reper

114 , icv infusion of the GLP-1 receptor agonist exendin 4 (Ex4) reduced insulin-stimulated muscle glucos

115 Evans rats were monitored for BW loss during exendin-4 (Ex4) administration.

116 In this study, we demonstrate a smart exendin-4 (Ex4) delivery device based on microneedle (MN

117 involving direct effects of a GLP-1 agonist, Exendin-4 (EX4) on food reward that are exerted at the l

118 Exendin-4 (Ex4), a glucagon-like peptide-1 receptor (GLP

119 Because exendin-4 (Ex4), a long acting glucagon-like peptide 1 r

120 intra-PVT delivery of either GLP-1R agonist, exendin-4 (Ex4), or GLP-1R antagonist, exendin-9-39 (Ex9

121 intraperitoneal injection of either GLP-1 or Exendin-4 (Ex4; a GLP-1 receptor agonist).

122 We report that GLP-1 and its agonist, exendin-4 (Exd4), induce Wnt signaling in pancreatic bet

123 ndle structure of GLP1R bound to the peptide Exendin-4 (Exe4; a GLP1R agonist on the market for treat

124 nal transport, were prevented by exposure to exendin-4 (exenatide), an anti-diabetes agent.

125 a- and 89Zr-radiolabeled [Lys40-(AHX-DFO)NH2]exendin-4 exhibit characteristics comparable or superior

126 bution experiments, [Lys40-(AHX-DFO-68Ga)NH2]exendin-4 exhibited a significantly enhanced tumor uptak

127 An exendin-4 expression system was constructed using the tw

128 TSTA exendin-4 expression system with SP and ABP polymer has

129 se (CICR), and cAMP-elevating agents such as exendin-4 facilitate CICR in beta-cells by activating bo

130 /scatter factor, betacellulin, activin A, or exendin-4 failed to induce pancreatic and duodenal homeo

131 This tannic acid/exendin-4/Fe(3+) ternary nanoparticle system holds trans

132 In this study, we developed a tannic acid/exendin-4/Fe(3+) ternary nanoparticle system to provide

133 one, or (pGlu-Gln)-CCK-8 in combination with exendin-4 for 21 days to high-fat-fed mice significantly

134 th the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs wi

135 l or aqueous glycol, the Leu21-Pro38 span of exendin-4 forms a compact tertiary fold (the Trp-cage) w

136 In this study, we demonstrate that exendin-4/GLP-1 has a cognate receptor on human hepatocy

137 g may represent a novel downstream target of exendin-4 (glucagon-like peptide 1) signaling and potent

138 Exendin-4, glucagon-like peptide 1 (GLP-1) receptor agon

139 Increased expression of exendin-4, glucose dependent insulin secretion in NIT-1

140 ic GLP-1R activation with the GLP-1R agonist exendin-4 had no effect on food intake, hindbrain c-fos

141 gnate receptor on human hepatocytes and that exendin-4 has a direct effect on the reduction of hepati

142 Exendin-4 has a helix-favoring glutamate as residue 16.

143 Exendin-4 has a more regular and less fluxional helix in

144 In addition, the diabetes drug exendin-4 has been associated with pancreatitis, whereas

145 Exendin-4 has been clinically adopted as an effective dr

146 ometal-labeled exendin-4, (18)F-TTCO-Cys(40)-exendin-4 has much lower kidney uptake.

147 Furthermore, it appears that exendin-4 has the same beneficial effects in vitro as th

148 When the Trp-cage forms, fraying of the exendin-4 helix occurs exclusively from the N-terminus;

149 th high encapsulation efficiency (~ 100%) of exendin-4, high payload capacity, and high degrees of un

150 HbA1c was reduced in the (pGlu-Gln)-CCK-8/exendin-4 hybrid and combined parent peptide treatment g

151 rapeutic utility of a novel (pGlu-Gln)-CCK-8/exendin-4 hybrid peptide compared with the stable GLP-1

152 administration of the novel (pGlu-Gln)-CCK-8/exendin-4 hybrid, (pGlu-Gln)-CCK-8 alone, or (pGlu-Gln)-

153 rred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.

154 All patients underwent (111)In-DTPA-exendin-4 imaging, 25 patients underwent surgery (with h

155 Exendin-4 improved insulin sensitivity in ob/ob mice, as

156 al mediator of beta-cell loss and shows that exendin-4 improves cell survival via restoration of lyso

157 Here, we developed an (18)F-labeled exendin-4 in high specific activity for islet imaging by

158 can reduce the renal accumulation of (111)In-exendin-4 in humans.

159 With the exception of exendin-4 in media containing fluoro alcohol cosolvents,

160 opic glutamate receptor (mGluR) agonists and exendin-4 in the brainstem.

161 fects of the glucagon-like peptide-1 agonist exendin-4 in transgenic mice paves the way for translati

162 Thus, to improve the activity of exendin-4 in vivo, gene therapy system was developed as

163 ticle system to provide sustained release of exendin-4 in vivo.

164 do not affect stimulation by GLP-1, GIP, or exendin-4 in wild-type islets, although they block phosp

165 ealthy volunteers received 50 MBq of (111)In-exendin-4, in combination with Gelofusine or saline, in

166 we report that GLP-1 and its stable analogue exendin-4 increase the action potential firing frequency

167 Exendin-4 increased acute-phase insulin release to a sim

168 Exendin-4 increased cAMP accumulation in purified IELs a

169 In cultured islets, exendin-4 increased cyclin A2 and Skp2 and reduced p27.

170 Exendin-4 increased the phosphorylation of 3-phosphoinos

171 rones where L-AP4 decreased mIPSC frequency, exendin-4 increased, while PP had no effect upon, mIPSC

172 iled to expand beta-cell mass in response to exendin-4, indicating that p16(Ink4a)levels are a critic

173 tor receptor (EGFR) null mouse, we show that exendin-4 induced an increase in proliferation and beta-

174 Exendin-4 induced proproliferative signaling pathways in

175 In voltage clamp, the GLP-1 agonist Exn4 (exendin-4) induced an inward current that reversed near

176 Ex vivo analyses show prolonged exendin-4-induced activation (live cell calcium signalin

177 -positive differentiation seems to entail an exendin-4-induced drop in smad 2 and elevation in smad 3

178 moted, whereas 26RFa inhibited, glucose- and exendin-4-induced insulin secretion, through Galphas and

179 Oligonucleotides anti-miR-7 inhibited the exendin-4-induced proliferation in normal rat cholangioc

180 kolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the shuttling of MondoA and potently

181 les had an AUC 7.2-fold higher than the free exendin-4 injection.

182 Results: Exendin-4-IRDye 800CW binds GLP-1R with a half-maximal i

183 Intraoperative lesion delineation using exendin-4-IRDye 800CW could benefit open as well as lapa

184 Results: Exendin-4-IRDye700DX has a high affinity for the GLP-1R,

185 The efficacy and specificity of rtPDT with exendin-4-IRDye700DX were examined in vitro in cells wit

186 r-targeted photodynamic therapy (rtPDT) with exendin-4-IRDye700DX, targeting the glucagon-like peptid

187 vivo evidence of the potency of rtPDT using exendin-4-IRDye700DX.

188 Exendin-4 is a GLP-1 agonist that is clinically used for

189 Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor

190 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-

191 Exendin-4 is a peptide agonist of the glucagon-like pept

192 (68)Ga-NODAGA-exendin-4 is a promising tracer for beta-cell imaging us

193 This sensitizing action of exendin-4 is diminished by an inhibitor of PKA (H-89) or

194 Exendin-4 is used to clinically improve glucose toleranc

195 ed Ca2+ (NP-EGTA), a GLP-1 receptor agonist (exendin-4) is demonstrated to sensitize intracellular Ca

196 )(Ahx-DOTA-(68)Ga)NH2]exendin-4 ((68)Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign

197 udy, we found that the potency of GLP-1, not exendin 4, is specifically enhanced by the endocannabino

198 R)-positive lesions, using the GLP-1 agonist exendin-4 labeled with IRDye 800CW, was examined in vitr

199 pancreata of Pdx1-Cre; LSL-Kras(G12D) mice, exendin-4 led to acceleration of the disruption of exocr

200 copy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptop

201 ion of a fluorophore-labeled GLP-1R agonist, exendin-4, localizes within astrocytes and neurons in th

202 Increases in Cx36 coupling with exendin-4 may protect against cytokine-mediated beta-cel

203 Increases in beta-cell coupling with exendin-4 may protect against cytokine-mediated beta-cel

204 bally, ECL2 mutation was more detrimental to exendin-4-mediated Ca(2+)i release than GLP-1(7-36)-NH(2

205 Exendin-4 microinjections increased plasma insulin.

206 MP signaling, of the incretin hormone analog exendin-4 on cell cycle regulation in beta-cells.

207 of DXM, amplified the stimulatory effect of exendin-4 on GSIS.

208 the role of EGFR signaling in the effects of exendin-4 on the control of blood glucose metabolism and

209 0.1, 1 nmol/L GLP-1 or 10, 50, or 100 nmol/L exendin-4, only the sIPSC frequency increased.

210 educed dietary fat along with PEG-leptin and exendin-4 or FGF21 cotreatment.

211 ated (PEG)-leptin analog in combination with exendin-4 or FGF21.

212 Exendin-4 or GLP-1-Tf (but not insulin) treatment also i

213 n content was increased in mice treated with exendin-4 or liraglutide.

214 h the glucagon-like peptide 1 (GLP-1) analog exendin-4, or after streptozotocin (STZ) administration.

215 tral site of action, we showed that systemic exendin-4 penetrated the brain and bound putative GLP-1

216 The fusion gene encodes a protein with exendin-4 peptide placed at the N-terminus of human alph

217 NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 performed similarly well.

218 (68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT wer

219 (68)Ga-DOTA-exendin-4 PET/CT correctly identified the insulinoma in

220 ary data suggest that the use of (68)Ga-DOTA-exendin-4 PET/CT in detecting hidden insulinomas is feas

221 fused surgery despite a positive (68)Ga-DOTA-exendin-4 PET/CT scan.

222 of a clinically used GLP-1 receptor agonist, exendin-4, potently increased the expression of IL-6 in

223 Exendin-4 preserved coupling in mouse islets by preservi

224 ent outcomes in terms of extended release of exendin-4, prolonged control of blood glucose level, red

225 In both mouse and human islets, exendin-4 protected against cytokine-induced decreases i

226 er loss of endothelial GLP-1R expression and exendin-4-protective actions and exhibited more albuminu

227 It is concluded that exendin-4 protects the CNS from damage due to cerebral i

228 Treatment with exendin-4 quantitatively reduced triglyceride stores com

229 Furthermore, the GLP-1 receptor agonist exendin-4 reduced CP-induced renal injury and apoptosis,

230 administration of the GLP-1 receptor agonist exendin-4 reduced oxycodone self-administration and the

231 Exendin-4 regulated Cx36 coupling via both protein kinas

232 ntraperitoneal injection in mice showed that exendin-4 released from the nanoparticles had an AUC 7.2

233 d into mice cured by treatment with ALS plus exendin-4 remained intact, and cotransfer of lymphocytes

234 Intraperitoneal administration of exendin-4 resulted in extensive FOS expression in areas

235 ed into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual

236 Cotreatment with the GLP-1 receptor agonist exendin-4 reversed the lysosomal dysfunction, relieving

237 CC agonist 2a and the Glp-1 receptor agonist Exendin-4 showed an additive effect on beta-cell replica

238 Mice treated with exendin-4 showed increased beta-cell proliferation, elev

239 rgistic and codependent relationship between exendin-4 signaling and TGF-beta isoform signaling.

240 (111)In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and

241 oma in 4 of 4 patients, whereas (111)In-DOTA-exendin-4 SPECT/CT correctly identified the insulinoma i

242 (111)In-DTPA-exendin-4 SPECT/CT could provide a good second-line imag

243 For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI

244 (111)In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient

245 68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-

246 ntified in separate patients by (111)In-DTPA-exendin-4 SPECT/CT.

247 Moreover, administration of GLP-1 agonist exendin-4 stimulated beta-cell proliferation in young bu

248 Exendin-4 stimulated cyclin A2 promoter activity via the

249 PDX-1 knockdown reduced exendin-4-stimulated cAMP synthesis and cyclin A2 transc

250 Antagonist 5d not only blocked exendin-4-stimulated insulin release in islets but also

251 In Min6 cells, cyclin A2 knockdown prevented exendin-4-stimulated proliferation.

252 A2 is required for beta-cell proliferation, exendin-4 stimulates cyclin A2 expression via the cAMP p

253 clin A2 expression via the cAMP pathway, and exendin-4 stimulation of cAMP requires PDX-1.

254 mia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agoni

255 rglycemia is normalized in mice treated with exendin-4, suggesting that this model can be effectively

256 These results show that exendin-4 synergistically augments the remission-inducin

257 d cholesterol to biologically active peptide exendin-4 that is an approved drug for the treatment of

258 o identified behaviorally selective doses of exendin-4 that reduced opioid-taking and -seeking behavi

259 ne expression in mice disrupts the action of exendin-4 to facilitate CICR in the beta-cells of these

260 This action of exendin-4 to facilitate CICR was reproduced by cAMP anal

261 naesthetized rat preparation, application of exendin-4 to the DVC decreased gastric tone in a concent

262 hx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinomas.

263 1 potency more than 40-fold, but not that of exendin 4, to stimulate cAMP production.

264 ddition of beta-cell growth factors, such as exendin-4, to immunotherapy protocols with anti-T-cell a

265 patic steatosis was significantly reduced in Exendin-4 treated ob/ob mice.

266 oxidative stress parameters were improved in exendin-4 treated rats compared to control.

267 Results indicate that exendin-4 treated rats had significant protection follow

268 3 mg/kg) on cerebral ischemia in control and exendin-4 treated rats.

269 cerebral ischemia was similar in vehicle or exendin-4 treated rats.

270 d 8) mRNAs were specifically up-regulated in exendin-4-treated AR42J cells.

271 endin-4 was also observed in the ABP/TSTA/SP-exendin-4-treated mice groups, compared with the others

272 cerebral ischemia which was not affected by exendin-4 treatment or by BQ123 administration.

273 Combining CFA with exendin-4 treatment significantly increased the insulin

274 ulin-positive differentiation in response to exendin-4 treatment, suggesting a role for BMP signaling

275 ke and body weight in response to peripheral exendin-4 treatment.

276 a reduction in the net weight gained during Exendin-4 treatment.

277 strongly support the notion that (68)Ga-DO3A-exendin-4 uptake in the pancreas is mediated by specific

278 The highest insulinotropic effect of exendin-4 was also observed in the ABP/TSTA/SP-exendin-4

279 that liver uptake of [(68)Ga]DO3A-VS-Cys(40)-Exendin-4 was approximately 6-fold higher in mice that r

280 systemically administered fluorophore-tagged exendin-4 was blocked by central pretreatment with the c

281 Tumor uptake of [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 was comparable to that of [Lys40-(AHX-DTPA-111

282 In the present study, (68)Ga-labeled exendin-4 was evaluated for PET imaging and quantificati

283 F-tetrazine trans-cyclooctene (TTCO)-Cys(40)-exendin-4 was evaluated in vitro with INS-1 cell and in

284 [Lys40-(AHX-DFO)NH2]exendin-4 was labeled with 89Zr and 68Ga in high radioch

285 (18)F-TTCO-Cys(40)-exendin-4 was obtained in high specific activity and cou

286 ntial efficacies in the CICR assay such that exendin-4 was partly effective, 6-Bnz-cAMP-AM was fully

287 [(68)Ga]DO3A-VS-Cys(40)-Exendin-4 was radiosynthesized and evaluated for PET ima

288 nically evaluated [Lys40-(AHX-DTPA-111In)NH2]exendin-4 was used as a reference compound.

289 Based on the amino acid sequence of exendin-4, we created a neopeptide via introduction of a

290 further improve the therapeutic efficacy of exendin-4, we have developed a novel peptide engineering

291 ymethylaza)cyclododecane-10-azaacetyl (DO3A)-exendin-4 were performed in rats (organ distribution) an

292 The gastroinhibitory effects of exendin-4 were unaffected by systemic pretreatment with

293 the glucagon-like peptide-1 receptor agonist exendin-4 were unchanged.

294 st 8-Br-Rp-cAMPS blocked CICR in response to exendin-4, whereas the PKA inhibitor H-89 was ineffectiv

295 macological treatments with the GLP-1 analog Exendin-4, which increased nuclear Hes3 localization.

296 The goal of this study was to determine if exendin-4, which increases cAMP, can protect against cyt

297 In both mouse and human islets exendin-4, which increases cAMP, protected against cytok

298 Tetrazine ligation was used to radiolabel exendin-4 with (18)F.

299 ch is composed of pbeta-Gal4-p65 and pUAS-SP-exendin-4 with combining the advantages of signal peptid

300 y was to determine whether administration of Exendin-4 would reverse hepatic steatosis in ob/ob mice.